SEARCH

SEARCH BY CITATION

References

  • 1
    Begg EJ, Barclay ML. Aminoglycosides – 50 years on. Br J Clin Pharmacol 1995; 39 (6): 597603.
  • 2
    Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47 (6): 63743.
  • 3
    Sheiner L, Tozer T. Clinical pharmacokinetics: The use of plasma concentrations of drugs. In: Melmon, K, Morelli, H, eds. Clinical Pharmacology: Basic Principles of Therapeutics. New York: Macmillan 1978, pp. 71109.
  • 4
    Holford NHG. Target Concentration Intervention: Beyond Y2K Br J Clin Pharmacol 1999; 48: 913.
  • 5
    Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 6059.
  • 6
    Kirkpatrick CM, Begg EJ, Barclay ML, Duffull SB. Aminoglycoside dosage regimens after therapeutic drug monitoring. Clin Pharmacokinetics 2002; 41 (10): 7912.
  • 7
    Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341 (8841): 3359.
  • 8
    Prins JM, Weverling GJ, De Blok K, Van Ketel RJ, Speelman P. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrobial Agents Chemotherapy 1996; 40 (11): 24949.
  • 9
    Holford NHG. Concentration controlled therapy. In: Breckenridge, A, ed. Esteve Foundation Workshop. Amsterdam: Elsevier Science 2001, pp. 13544.
  • 10
    Weinstein MJ, Ludemann GM, Oden EM, Wagman GH, Rosselet JP, Marquez JA, et al. Gentamicin a new antibiotic complex from micromonospora. J Med Chem 1963; 6 (4): 4634.
  • 11
    Rosario MC, Thomson AH, Jodrell DI, Sharp CA, Elliott HL. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998; 46 (3): 22936.
  • 12
    Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43 (2): 12535.
  • 13
    Hickling KG, Begg EJ, Perry RE, Atkinson HC, Sharman JR. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Crit Care Med 1991; 19 (8): 10417.
  • 14
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 3141.
  • 15
    Wheeler LA, Sheiner LB. Clinical estimation of creatinine clearance. Am J Clin Pathol 1979; 72 (1): 2732.
  • 16
    Jelliffe RW. Letter: Creatinine clearance: bedside estimate. Ann Intern Med 1973; 79 (4): 6045.
  • 17
    Jelliffe RW. Estimation of creatinine clearance when urine cannot be collected. Lancet 1971; 1 (7706): 9756.
  • 18
    Edwards KDJ, Whyte HM. Plasma creatinine level and creatinine clearance as tests of renal function. Aust Ann Med 1959; 8: 21833.
  • 19
    Schneider Va, HenschelVb Tadjalli-Mehr Ka, Mansmann Ub Haefeli Wa. Impact of serum creatinine measurement error on dose adjustment in renal failure. Clin Pharmacol Therapeutics 2003; 74 (5): 45867.
  • 20
    Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13 (8): 21404.
  • 21
    Beal SL, Boeckmann AJ, Sheiner LB, NONMEM Project Group. NONMEM Users Guides. In: Version, V, eds. University of California at San Francisco, San Francisco; 1999.
  • 22
    Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinetics 1996; 30: 32932.
  • 23
    West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276: 1226.
  • 24
    West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284 (5420): 16779.
  • 25
    Davison AC, Hinkley DV. Bootstrap Methods and Their Application. Cambridge: Cambridge University Press 1997.
  • 26
    Sheiner LB, Beal SL. Some Suggestions for Measuring Predictive Performance. J Pharmacokinetics Biopharmaceutics 1981; 9 (4): 50312.
  • 27
    Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Therapeutics 1977; 22 (3): 36470.
  • 28
    Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001; 84 (4): 4529.
  • 29
    Contrepois A, Brion N, Garaud JJ, Faurisson F, Delatour F, Levy JC, et al. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob Agents Chemother 1985; 27 (4): 5204.
  • 30
    Regamey C, Gordon RC, Kirby WM. Comparative pharmacokinetics of tobramycin and gentamicin. Clin Pharmacol Ther 1973; 14 (3): 396403.
  • 31
    Kaloyanides GJ. Antibiotic-related nephrotoxicity. Nephrol Dialysis Transplantation 1994; 9(Suppl 4): 1304.
  • 32
    Hashino E, Shero M, Salvi RJ. Lysosomal augmentation during aminoglycoside uptake in cochlear hair cells. Brain Res 2000; 887 (1): 907.
  • 33
    Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990; 40 (11): 238392.
  • 34
    Schanck A, Mingeot-Leclercq MP, Tulkens PM, Carrier D, Smith ICP, Jarrell HC. Interactions of aminoglycoside antibiotics with phospholipids. A deuterium nuclear magnetic resonance study. Chem Physics Lipids 1992; 62 (2): 15363.
  • 35
    Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39 (6): 67786.
  • 36
    Buabeng KO, Mackenzie AR, Laing RBS, Cook I, Jappy B, Gould IM. Assessment of the efficacy, safety and quality of gentamicin use in Aberdeen Royal Infirmary. J Antimicrob Chemother 1999; 44 (6): 8435.
  • 37
    Wallace AW, Jones M, Bertino JS. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 2002; 22 (9): 107783.